Inclisiran in the Spotlight: The VICTORION-Mono Trial Shakes Up Primary Prevention Breaking New Ground in LDL-C Management A landmark study, VICTORION‑Mono (V‑Mono), reveals that inclisiran—a twice-yearly, small interfering RNA (siRNA) designed to inhibit PCSK9—is significantly more effective than both placebo … Read More
